Overview

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Status:
NOT_YET_RECRUITING

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

This is a single-arm, sequential study assessing the efficacy and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced non-small cell lung cancer (NSCLC) : first-line treatment or failed from first-line immune checkpoint inhibitor treatment.The primary objective is to evaluate the anti-tumor activity and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced NSCLC.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Fujian Cancer Hospital

Treatments:

Carboplatin
Cisplatin
Docetaxel
Paclitaxel
Pemetrexed
toripalimab